Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Perspective Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Perspective Therapeutics, Inc.’s stock price such as:

• Perspective Therapeutics, Inc.’s current stock price and volume
• Why Perspective Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CATX from analysts
• CATX’s stock price momentum as measured by its relative strength

About Perspective Therapeutics, Inc. (CATX)

Before we jump into Perspective Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Want to learn more about Perspective Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Perspective Therapeutics, Inc..

Perspective Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Perspective Therapeutics, Inc.’s stock price was $2.910.

Perspective Therapeutics, Inc. is down 2.68% from its previous closing price of $2.990.

During the last market session, Perspective Therapeutics, Inc.’s stock traded between $2.830 and $3.040. Currently, there are approximately 103.60 million shares outstanding for Perspective Therapeutics, Inc..

Perspective Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Perspective Therapeutics, Inc. Stock Price History

Perspective Therapeutics, Inc.’s (CATX) price is currently down 14.66% so far this month.

During the month of July, Perspective Therapeutics, Inc.’s stock price has reached a high of $3.780 and a low of $2.690.

Over the last year, Perspective Therapeutics, Inc. has hit prices as high as $6.160 and as low as $1.955. Year to date, Perspective Therapeutics, Inc.’s stock is up 5.82%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Perspective Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Perspective Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Perspective Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Perspective Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Perspective Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Perspective Therapeutics, Inc. (CATX) by visiting AAII Stock Evaluator.

Relative Price Strength of Perspective Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Perspective Therapeutics, Inc. has a weighted four-quarter relative price strength of -10.70%, which translates to a Momentum Score of 23 and is considered to be Weak.

Want to learn more about how Perspective Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Perspective Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Perspective Therapeutics, Inc.’s stock price is $2.910, which is down 2.68% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Perspective Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.